Welcome to our dedicated page for Alpha Tau Medical SEC filings (Ticker: DRTSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alpha Tau Medical Ltd.'s SEC filings document foreign private issuer reports for a clinical-stage oncology company developing Alpha DaRT for solid tumors. Recent Form 6-K reports furnish press releases and company presentations covering clinical data, trial progress, regulatory submissions, and conference-call materials for programs such as ReSTART in recurrent cutaneous squamous cell carcinoma and REGAIN in recurrent glioblastoma.
The filings also identify disclosure mechanics for furnished exhibits, incorporation by reference into registration statements, and Exchange Act treatment of company presentations and press releases. For this issuer, the filing record centers on clinical-development disclosures, FDA-related PMA and IDE context, regulatory-risk language, capital-market registration references, and public-company reporting obligations.
Alpha Tau Medical Ltd. director Alan Adler filed an initial ownership report showing his equity stake in the company. He directly holds 54,367 Ordinary Shares and 4,680 restricted share units, which will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
Adler also reports multiple option grants to acquire Ordinary Shares, with exercise prices ranging from $2.98 to $11.50 per share and expiration dates between 2028 and 2036. Some of these options are already fully vested, while others vest on the same future schedule tied to the March 9, 2026 date or the next Annual General Meeting.
Alpha Tau Medical Ltd. director Alan Adler filed an initial ownership report showing his equity stake in the company. He directly holds 54,367 Ordinary Shares and 4,680 restricted share units, which will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
Adler also reports multiple option grants to acquire Ordinary Shares, with exercise prices ranging from $2.98 to $11.50 per share and expiration dates between 2028 and 2036. Some of these options are already fully vested, while others vest on the same future schedule tied to the March 9, 2026 date or the next Annual General Meeting.
Alpha Tau Medical Ltd. director Blumenfeld S. Morry filed an initial Form 3 reporting his existing equity position. He directly holds 155,771 Ordinary Shares of Alpha Tau Medical and 4,680 Restricted Share Units, which will vest in full on the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
He also reports multiple option grants over Ordinary Shares at exercise prices ranging from $2.98 to $11.50 per share, with expirations between 2028 and 2036. Footnotes indicate that some options are already fully vested, while others will vest in their entirety on the same schedule tied to March 9, 2026 or the next Annual General Meeting.
Alpha Tau Medical Ltd. director Blumenfeld S. Morry filed an initial Form 3 reporting his existing equity position. He directly holds 155,771 Ordinary Shares of Alpha Tau Medical and 4,680 Restricted Share Units, which will vest in full on the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
He also reports multiple option grants over Ordinary Shares at exercise prices ranging from $2.98 to $11.50 per share, with expirations between 2028 and 2036. Footnotes indicate that some options are already fully vested, while others will vest in their entirety on the same schedule tied to March 9, 2026 or the next Annual General Meeting.
Alpha Tau Medical Ltd. director David Mark Milch filed an initial Form 3 reporting his beneficial ownership in the company. He holds several tranches of options to acquire ordinary shares, including 8,945 shares at an exercise price of $10.9200 and 10,178 shares at $7.1900, along with larger grants at lower prices that expire between 2032 and 2036.
He also reports 49,000 warrants to acquire ordinary shares held indirectly through Healthcare Capital Sponsor LLC, 29,367 ordinary shares held directly, 88,743 ordinary shares held indirectly through the same entity, and 4,680 restricted share units that will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
Alpha Tau Medical Ltd. director David Mark Milch filed an initial Form 3 reporting his beneficial ownership in the company. He holds several tranches of options to acquire ordinary shares, including 8,945 shares at an exercise price of $10.9200 and 10,178 shares at $7.1900, along with larger grants at lower prices that expire between 2032 and 2036.
He also reports 49,000 warrants to acquire ordinary shares held indirectly through Healthcare Capital Sponsor LLC, 29,367 ordinary shares held directly, 88,743 ordinary shares held indirectly through the same entity, and 4,680 restricted share units that will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
Alpha Tau Medical Ltd. director Alon Ruth filed an initial ownership report detailing his equity position in the company. He directly holds 29,367 ordinary shares, 4,680 restricted share units that vest in full upon the earlier of one year from March 9, 2026 or the next annual shareholder meeting, and multiple option grants over ordinary shares with exercise prices between $2.98 and $10.92. According to the footnotes, certain options are already fully vested, while others vest on the same future schedule as the restricted share units, all subject to his continued service.
Alpha Tau Medical Ltd. director Alon Ruth filed an initial ownership report detailing his equity position in the company. He directly holds 29,367 ordinary shares, 4,680 restricted share units that vest in full upon the earlier of one year from March 9, 2026 or the next annual shareholder meeting, and multiple option grants over ordinary shares with exercise prices between $2.98 and $10.92. According to the footnotes, certain options are already fully vested, while others vest on the same future schedule as the restricted share units, all subject to his continued service.
Alpha Tau Medical Ltd. director Netser Maya filed an initial ownership report detailing current equity interests in the company. The filing shows direct ownership of 3,086 ordinary shares.
Maya also holds restricted share units representing 4,321 ordinary shares that vest in equal monthly installments over three years commencing on December 17, 2024, subject to continued service. An additional 4,680 restricted share units will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, also conditioned on continued service.
The report lists stock options to acquire 24,048 ordinary shares at an exercise price of $4.05 per share, vesting in equal monthly installments over three years commencing December 17, 2024, and expiring on January 22, 2035. Further options cover 15,527 ordinary shares at an exercise price of $6.41 per share, vesting in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, with an expiration date of March 9, 2036.
Alpha Tau Medical Ltd. director Netser Maya filed an initial ownership report detailing current equity interests in the company. The filing shows direct ownership of 3,086 ordinary shares.
Maya also holds restricted share units representing 4,321 ordinary shares that vest in equal monthly installments over three years commencing on December 17, 2024, subject to continued service. An additional 4,680 restricted share units will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, also conditioned on continued service.
The report lists stock options to acquire 24,048 ordinary shares at an exercise price of $4.05 per share, vesting in equal monthly installments over three years commencing December 17, 2024, and expiring on January 22, 2035. Further options cover 15,527 ordinary shares at an exercise price of $6.41 per share, vesting in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, with an expiration date of March 9, 2036.
Alpha Tau Medical Ltd. executive Raphi Levy, the Chief Financial Officer, reports his current equity holdings in the company. He directly holds 180,180 ordinary shares, multiple option grants over ordinary shares with exercise prices ranging from 2.60 to 11.50 and expirations between 2029 and 2036, and several tranches of restricted share units.
The footnotes explain that certain restricted share unit grants vest in equal quarterly installments over three-year periods commencing January 1, 2024, January 1, 2025 and January 1, 2026, subject to his continued service. Some option grants are already fully vested, while others vest quarterly over similar three-year schedules tied to continued employment.
Alpha Tau Medical Ltd. executive Raphi Levy, the Chief Financial Officer, reports his current equity holdings in the company. He directly holds 180,180 ordinary shares, multiple option grants over ordinary shares with exercise prices ranging from 2.60 to 11.50 and expirations between 2029 and 2036, and several tranches of restricted share units.
The footnotes explain that certain restricted share unit grants vest in equal quarterly installments over three-year periods commencing January 1, 2024, January 1, 2025 and January 1, 2026, subject to his continued service. Some option grants are already fully vested, while others vest quarterly over similar three-year schedules tied to continued employment.
Alpha Tau Medical reported a larger net loss for 2025 while advancing its Alpha DaRT cancer therapy and strengthening its balance sheet. The company posted a 2025 net loss of $42.6 million, or $0.53 per share, compared with a $31.8 million loss, or $0.45 per share, in 2024, driven mainly by higher research and development and general and administrative costs.
R&D expenses rose to $32.1 million from $27.0 million, and G&A increased to $8.4 million from $6.7 million, while marketing expenses declined slightly. Despite the wider loss, cash, cash equivalents, short-term deposits and restricted deposits increased to $76.9 million as of December 31, 2025, up from $62.9 million a year earlier, supporting ongoing trials and commercial preparations. Recent milestones include Japanese marketing approval for Alpha DaRT, a fifth parallel U.S. trial approval, first brain cancer treatment using Alpha DaRT, and progress across pancreatic and glioblastoma studies.
Alpha Tau Medical reported a larger net loss for 2025 while advancing its Alpha DaRT cancer therapy and strengthening its balance sheet. The company posted a 2025 net loss of $42.6 million, or $0.53 per share, compared with a $31.8 million loss, or $0.45 per share, in 2024, driven mainly by higher research and development and general and administrative costs.
R&D expenses rose to $32.1 million from $27.0 million, and G&A increased to $8.4 million from $6.7 million, while marketing expenses declined slightly. Despite the wider loss, cash, cash equivalents, short-term deposits and restricted deposits increased to $76.9 million as of December 31, 2025, up from $62.9 million a year earlier, supporting ongoing trials and commercial preparations. Recent milestones include Japanese marketing approval for Alpha DaRT, a fifth parallel U.S. trial approval, first brain cancer treatment using Alpha DaRT, and progress across pancreatic and glioblastoma studies.
Alpha Tau Medical Ltd. files its annual Form 20‑F as a clinical‑stage oncology company developing its Alpha DaRT local alpha‑radiation technology for solid tumors. The company has no product revenue and reported net losses of $31,750 and $42,627 for the years ended December 31, 2024 and 2025, respectively, with an accumulated deficit of $190,136 as of December 31, 2025.
As of that date, Alpha Tau had 88,009,737 ordinary shares outstanding. In April 2025 it sold 14,110,121 ordinary shares to Oramed Ltd. at $2.612 per share, generating net proceeds of about $36.7 million, and believes existing cash should fund operations for at least the next two years. The filing emphasizes extensive risks around ongoing losses, future funding needs, stringent global device regulation, clinical trial uncertainty and potential product liability as it seeks marketing authorization for Alpha DaRT across multiple cancer indications.
Alpha Tau Medical Ltd. files its annual Form 20‑F as a clinical‑stage oncology company developing its Alpha DaRT local alpha‑radiation technology for solid tumors. The company has no product revenue and reported net losses of $31,750 and $42,627 for the years ended December 31, 2024 and 2025, respectively, with an accumulated deficit of $190,136 as of December 31, 2025.
As of that date, Alpha Tau had 88,009,737 ordinary shares outstanding. In April 2025 it sold 14,110,121 ordinary shares to Oramed Ltd. at $2.612 per share, generating net proceeds of about $36.7 million, and believes existing cash should fund operations for at least the next two years. The filing emphasizes extensive risks around ongoing losses, future funding needs, stringent global device regulation, clinical trial uncertainty and potential product liability as it seeks marketing authorization for Alpha DaRT across multiple cancer indications.
DRTS submitted a Form 144 notice identifying a proposed sale of 10,000 ordinary shares through Oppenheimer & Co. Inc.
The filing also lists 87,500 restricted stock units dated 08/08/2021 and records a prior sale by Levy Raphi of 60,000 ordinary shares on 01/08/2026 for $404,674.46.
DRTS submitted a Form 144 notice identifying a proposed sale of 10,000 ordinary shares through Oppenheimer & Co. Inc.
The filing also lists 87,500 restricted stock units dated 08/08/2021 and records a prior sale by Levy Raphi of 60,000 ordinary shares on 01/08/2026 for $404,674.46.
Alpha Tau Medical Ltd. reported that Japan’s Ministry of Health, Labour and Welfare has granted Shonin marketing approval for its Alpha DaRT® therapy to treat unresectable locally advanced or locally recurrent head and neck cancer. This is the first regulatory approval for the Alpha DaRT platform outside Israel.
As a condition of approval, the company will run a post-market surveillance study in Japan, enrolling 66 patients across five leading clinical centers to further evaluate safety and clinical performance. Alpha Tau and its partner HekaBio are preparing for launch and plan discussions with Japanese authorities about potential reimbursement and additional clinical studies in other tumor types.
Alpha Tau Medical Ltd. reported that Japan’s Ministry of Health, Labour and Welfare has granted Shonin marketing approval for its Alpha DaRT® therapy to treat unresectable locally advanced or locally recurrent head and neck cancer. This is the first regulatory approval for the Alpha DaRT platform outside Israel.
As a condition of approval, the company will run a post-market surveillance study in Japan, enrolling 66 patients across five leading clinical centers to further evaluate safety and clinical performance. Alpha Tau and its partner HekaBio are preparing for launch and plan discussions with Japanese authorities about potential reimbursement and additional clinical studies in other tumor types.